Pioneering New Therapies for Liver Disease
Along with providing quality care to our patients, our expert clinicians at Stanford Hospital’s Liver Transplant Program actively research cutting-edge treatment programs that will help improve the lives of our patients.
Building on a long history of innovation, our team at Stanford is revolutionizing transplantation with ongoing advances in immunology and clinical immunosuppression. We are committed to new developments that minimize side effects of long-term immunosuppression and safely increase the opportunity for transplant.
You can also visit Stanford’s Institute for Immunity Transplantation and Infection which aims to understand and ultimately control how the immune system defends the body at the molecular and cellular levels.
Current Stanford Studies & Trials:- PII of SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation. Daniel T Chang, Lewis K Shin, Pamela Kunz, Albert Koong, George Albert Fisher, Clark Andrew Bonham, Aijaz Ahmed
- Risk Factors and Molecular Genomics of U.S. Patients with Chronic Liver Disease & Hepatocellular CA. Aijaz Ahmed, Ramsey Cheung, Carlos Esquivel, Mindie H. Nguyen
- An Investigational Plan Evaluating the Operative Management of Parenchymal Bleeding by Means of an Adjunctive Application of BioFoam Surgical Matrix in Liver Surgery. Marc L. Melcher, Carlos Esquivel, Waldo Concepcion, Clark Andrew Bonham
- Acute liver failure at 26 weeks' gestation in a patient with sickle cell disease. Greenberg M, Daugherty TJ, Elihu A, Sharaf R, Concepcion W, Druzin M, Esquivel CO. Liver Transpl. 2009; 15 (10): 1236-41